Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03741127 · ClinicalTrials.gov registry record · Phase 1

Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

A Phase 1 study of Multiple Myeloma, sponsored by Poseida Therapeutics.

Active
Registry status
Phase 1
Development phase
100
Enrollment target
13
Study locations

NCT03741127 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Poseida Therapeutics. The registered enrollment target is 100 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower). The trial reports 13 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03741127, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Poseida Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
13
Study locations

Study Summary

Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Rimiducid may be administered as indicated

Study Locations (13)

California

  • University of California Davis - Davis
  • University of California, San Diego - San Diego
  • University of California San Francisco - San Francisco

Maryland

  • University of Maryland Greenebaum Comprehensive Cancer Center - Baltimore
  • Johns Hopkins University - Baltimore

Tennessee

  • Sarah Cannon Research Institute at Tennessee Oncology - Nashville
  • Vanderbilt University Medical Center - Nashville

Colorado

  • Colorado Blood Cancer Institute - Denver

Illinois

  • University of Chicago - Chicago

Kansas

  • University of Kansas Cancer Center - Westwood

Michigan

  • Wayne State - Karmanos Cancer Institute - Detroit

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2018-10-29
Est. Completion 2032-11
Phase Phase 1

Sponsor

Poseida Therapeutics

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03741127

The ClinicalTrials.gov registry entry for NCT03741127 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower). The listed sponsor is Poseida Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Rimiducid may be administered as indicated is the first listed.

NCT03741127 reports 13 study locations spanning 9 distinct geographic areas - top geographies include California, Maryland, Tennessee.

Frequently Asked Questions

What is clinical trial NCT03741127 about?

NCT03741127 is a clinical study titled "Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101". Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to as...

What is the current status of trial NCT03741127?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2018-10-29. Estimated completion is 2032-11.

What conditions does trial NCT03741127 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT03741127?

The interventions under investigation include: Rimiducid may be administered as indicated (DRUG).

Who is sponsoring clinical trial NCT03741127?

This trial is sponsored by Poseida Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03741127 being conducted?

This trial has 13 study locations across California, Colorado, Illinois, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.